Criteria to qualify for study: Drug used in study:
  • One prior line of therapy (defined as either one non-transplant regimen such as Mel-Dex of Vel-Dex or CyBorD.
  • One autologous stem cell transplant or one regimen of non-transplant induction therapy followed by a single autologous stem cell transplant (without hematologic progression between induction and ASCT).
  • Measuable hematologic disease as defined by serum differential free light chain concentration (Dflc, difference between amyloid forming [involved] and nonamyloid forming [uninvolved] free light chain [FLC] >50mg/L). Key exclusion criteria include Amyloidosis due to mutations of the transthyretin gene.

AMY 06 2016-200

Randomized Phase 2 trial of Lenalidomide/Dexamethasone/Elotuzumab +/- Cyclophosphamide followed by Lenalidomide/Dexamethasone/Elotuzumab maintenance as second-line therapy for patients with relapsed AL Amyloidosis.